NEW YORK (360Dx) – The US Food and Drug Administration recently launched an innovation challenge through which it hopes to advance the development of promising technologies for in vitro diagnostics that help combat the opioid crisis.

As part of the innovation challenge, the agency will work closely with selected candidates to help them achieve accelerated approvals to market their technologies, the agency said. Ultimately, its objective is to identify technologies and solutions that target pain, addiction, and diversion.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.